Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Six patients with recurrent and/or refractory acute nonlymphocytic leukemia (ANLL) were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) and cytotoxic agents administered simultaneously. Neither of the two patients who received cytosine arabinoside (ara-C) in combination with G-CSF achieved complete remission. The other four patients, who received multi-drug combination therapy together with G-CSF, all achieved complete remission. No major side effects due to G-CSF were observed. These results demonstrated that the effects of G-CSF in enhancing the sensitivity of leukemic cells to cytotoxic agents and accelerating the recovery of leukocytes could lead to its possible use in the treatment of ANLL.
Hanazono
Y
Y
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Miyazono
K
K
Piao
Y F
YF
Taketazu
F
F
Chiba
S
S
Miyagawa
K
K
Hirai
H
H
Sakamoto
S
S
Miura
Y
Y
Yazaki
Y
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004351:Drug Resistance; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000628:therapy; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction
D007155:Immunologic Factors; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; C015019:enocitabine; D008942:Mitoxantrone; D003630:Daunorubicin